|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Santen Pharmaceutical and Clearside Biomedical Enter Into Financing and Research Collaboration Agreements for Posterior Ocular Disease
1/31/2013 10:18:08 AM
EMERYVILLE, Calif. & ALPHARETTA, Ga.--(BUSINESS WIRE)--Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd. (Osaka, Japan, Ticker Code 4536JP), and Clearside Biomedical, Inc. announced today that Santen Ltd., the parent company of Santen Inc., has made an investment in Clearside Biomedical Inc. and has also entered into a research collaboration agreement for posterior ocular diseases. Santen will join with other investors to fund an additional $7.9 million for continued development of CLS1001 into pivotal testing and to further Clearside Biomedical’s pipeline in ocular choroidal neovascularization and inflammatory diseases of the posterior segment. Santen, along with new investor Mountain Group Capital and its affiliates join current investors Hatteras Venture Partners, Georgia Research Alliance Venture Fund, and Kenan Flagler Business School Private Equity Fund.
|
|
|
|
|
|
|
|
|
|
|